Is the domestic version of Eltrombopag/Eltrombopag on the market?

Eltrombopag is an oral thrombopoietin receptor agonist, mainly used to treat chronic immune thrombocytopenia (ITP), aplastic anemia (AA) and chronic hepatitis C-related thrombocytopenia. For a long time, the price of Eltrombopag’s original drug has been relatively high, which has brought a heavy financial burden to patients. However, with the launch of the domestic version of eltrombopag, this situation is gradually changing, providing patients with more choices.

The launch of domestically produced Eltrombopag not only reduces the price of the drug, but also improves its accessibility. The price of the original drug is usually several thousand yuan per box, while the price of the domestic version may be half or even lower than the original drug. This is undoubtedly a huge economic boon for patients who need to take long-term medication. In addition, the domestically produced Eltrombopag is equivalent to the original drug in terms of efficacy and safety, and has passed strict clinical trials and quality control to ensure the reliability and effectiveness of the drug.

The indications of domestic Eltrombopag are the same as those of the original drug. It is mainly used to increase platelet count and reduce the risk of bleeding. For patients with chronic ITP, domestic eltrombopag can effectively increase platelet levels and improve quality of life; for patients with aplastic anemia, it can be used as an auxiliary drug for immunosuppressive treatment to help restore hematopoietic function. In addition, the launch of domestically produced drugs has also promoted the coverage of medical insurance policies. Patients in some areas can already reimburse part of their expenses through medical insurance, further reducing economic pressure.

Although domestic Eltrombopag has advantages in terms of price and accessibility, patients still need to strictly follow the doctor's instructions when using it and regularly monitor platelet count and liver function to ensure the safety and efficacy of the drug. For patients who are using original drugs and need to switch to the domestic version, they should make gradual adjustments under the guidance of a doctor to avoid affecting the therapeutic effect due to drug switching.

Reference materials:https://go.drugbank.com/drugs/DB06210